Q4-rapporten kom in i med våra prognoser efter vinstvarningen.
Redeye notes a substantial sales contribution from distributors, in which Thermo Fisher sales are re...
Redeye is encouraged by the upbeat Q4 report showing solid top-line numbers and a small profit on EB...
Beijer Alma levererar ett kvartal med både organisk och förvärvdriven tillväxt trots en svagare indu...
Redeye comments on Fortnox’s Q4 report, showing underlying numbers largely matching our expectations...
Redeye comments on Nekkar’s Q4’24 report that beat our expectations mainly driven by higher activity...
ExpreS2ion Biotechnologies har påbörjat screening av deltagare i bolagets fas 1-studie med vaccinkan...
Redeye provides an initial take following the release of SenzaGen’s Q4 2024 report.
Redeye’s initial take on Stille’s year-end report is positive.
Redeye provides an initial take following the release of Optomed’s Q4 2024 report.
Redeye comments on Embracer’s Q3-results which were in line with the preannounced results.
Redeye comments on Thunderful Group’s Q4’24 report, which came in better than expected in terms of s...
VibroSense redovisade en nettoomsättning om 0,46 MSEK (0,57) i kvartalet, vilket var en minskning me...
Redeye comments on Polygiene Group´s fourth quarter of the year.
Minor estimate revisions To achieve run-rate output in new factories in H2'27e '25e EV/EBIT 7-8x Ba...
Redeye provides an update on Xspray Pharma following its year-end report, which revealed no major su...
Atria reported Q4 adjusted EBIT of EUR 13.2m, 19% (EUR 3.
Redeye comments on Carasent’s Q4 report, showing slightly softer numbers than expected.
Taaleri delivered a solid Q4, with continued earnings growth of 6% y/y and EBIT of EUR 9.
NoHo Partners' Q4 2024 results came in clearly above Vara Research consensus, as the company continu...